Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Africa Oxford Initiative (AfOx) invites applications for the 2019 AfOx Visiting Fellowships Programme. Our programme is designed to enhance academic mobility and network building. We support African scholars and researchers working over various areas to spend periods of flexible time in Oxford.

AfOx Team

The Africa Oxford initiative seeks to appoint visiting fellows from Universities and research institutions in Africa at partner Colleges in the University of Oxford.

The fellowship aims to facilitate collaborations, as well a foster research and teaching excellence in African institutions and in the University of Oxford.

The fellowship is for a duration of 4-8 weeks, to be taken up from July to September 2019. Applicants should be legal residents of an African country, holding an appointment in an academic or research institution in an African country.

There are four fellowship schemes to apply for this year: The AfOx Collaborative Fellowship, The AfOx-ASC Fellowship, The AfOx Law Fellowship and The AfOx TORCH Fellowship.

Application deadline: 24th January 2019 at midnight.

Read more

Similar stories

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

UK National Health Service begins rollout of Oxford coronavirus vaccine

@Oxford General

The first patients are being vaccinated as part of the UK’s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, at the Oxford University NHS Hospitals Trust. The Oxford AstraZeneca vaccinations will be delivered at a small number of hospitals for the first few days for surveillance purposes, as is standard practice, before the bulk of supplies are sent to hundreds of GP-led services later in the week.

Susie Dunachie awarded flagship NIHR career development award

@Oxford Awards & Appointments

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

AfOx receives the Wellcome Institutional Strategic Support Fund to launch the Africa Health Innovation Platform

@Oxford

AfOx in collaboration with partners across the UK and Africa has received a Wellcome Institutional Strategic Support Fund to establish an Africa Health Innovation Platform. The multi-disciplinary platform will support African innovators who develop new solutions to Africa’s health challenges, bringing together researchers, entrepreneurs, investors, technologists, policymakers, and change leaders to develop new approaches towards prevention, early detection and treatment of diseases.

The COVID-19 vaccine: do we know enough to end the pandemic?

@Oxford MORU

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.